Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock transaction creating a major central nervous system biopharmaceutical company. The combined entity will generate approximately $2.2 billion in annual revenue,
More
The Section 232 pharmaceutical tariff regime is no longer a looming threat for the industry — it is now active law following the July 31, 2026, deadline. President Trump’s April 2, 2026,
More
When a construction project goes wrong due to defective plans, slow RFI responses, or owner interference, the financial pain can be severe and very real. Costs pile up quickly, and contractors are
More
In March 2026, a coalition of trade groups filed a federal lawsuit challenging California’s SB 343, widely known as the Truth in Recycling Act. Plaintiffs argue the law unconstitutionally restricts truthful commercial
More
Private enforcers have issued over 2,600 notices of violation in California so far in 2026, with food, personal care, and apparel companies remaining the primary targets. The continued proliferation of Prop 65
More
Blanche has issued a memo claiming to rescind the Trump ally slush fund, a move that could be enough to advance his nomination out of committee. The memo is not in the
More
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, marking the steepest single-day decline across the entire FTSE 100 index. The sell-off came after reports emerged that Britain’s largest drugmaker
More
Palantir Technologies (PLTR) has emerged as one of the most closely watched stocks in the market, with investors tracking its AI-driven growth trajectory with considerable interest. The company has built a reputation
More
The FTSE 250 index, which tracks mid-sized companies listed on the London Stock Exchange, has long been considered a barometer of the domestic UK economy. Unlike the FTSE 100, which is heavily
More
Reform UK deputy leader Richard Tice is under investigation by the parliamentary standards watchdog for allegedly failing to declare an interest during a parliamentary debate. Daniel Greenberg, the parliamentary standards commissioner, confirmed
More